Welcome to our dedicated page for Alder news (Ticker: ALDR), a resource for investors and traders seeking the latest updates and insights on Alder stock.
This page contains historical news coverage for Alder Biopharmaceuticals, Inc. (ALDR), which operated as a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for migraine prevention and neurological disorders. The company has since undergone a corporate transformation, with its assets transferred to Lengo Therapeutics. This archive provides context on the company's history and the events leading to its transformation.
Historical news for Alder Biopharmaceuticals includes coverage of clinical trial developments, drug candidate progress, and corporate announcements related to its monoclonal antibody programs. For clinical-stage biotechnology companies, news typically centered on trial results, regulatory milestones, partnership announcements, and financing activities necessary to fund expensive drug development programs.
This historical archive documents Alder's journey as an independent biopharmaceutical company, including updates on its migraine prevention candidates and other antibody therapies in development. The news coverage captures the company's research activities, clinical progress, and ultimately the corporate transformation that concluded its operation as a standalone entity.
Lengo Therapeutics announces the appointment of new executive leaders, including Dr. Paul Pearson as Chief of Development, Dr. Eric Gruff as SVP of CMC, and Ingrid Simms as SVP and Principal Accounting Officer. Their extensive experience in R&D, manufacturing, and finance is expected to enhance the company's drug development efforts, particularly as its lead candidate progresses to clinical trials. Dr. Pearson and Dr. Gruff previously collaborated on the development of CALQUENCE®, a successful BTK inhibitor.
